Fluvastatin in the Therapy of Acute Coronary Syndrome

Novartis1,000 enrolled

Overview

This study is to evaluate the safety and efficacy of fluvastatin versus placebo, dosed shortly after or immediately when the coronary event occurs.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

1,000

Conditions

Coronary Disease Myocardial Infarction

Interventions

FluvastatinDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Acute coronary syndrome * Adults, 18 years and older Exclusion Criteria: * History of lipid lowering therapy less than 30 days before index event * Pregnancy and nursing * Subject younger than 18 years Other inclusion and exclusion criteria may apply.

Locations (1)

Novartis

Prague, Czechia

Outcomes

Primary Outcomes

Change from baseline in circulating markers of inflammation after 4 weeks and after 52 weeks

Secondary Outcomes

Occurrence of death, nonfatal myocardial infarction, cardiac arrest with resuscitation, recurrent symptomatic ischemia, and urgent revascularization after 4 weeks and after 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.